No treatment cures patients with the indolent forms of CTCLs, such as mycosis fungoides (MF)/ Sezary syndrome (SS) and lymphomatoid papulosis (LyP). Prognosis and survival of patients with CTCL remains dependent upon overall clinical staging and response to therapy. Over the last decade, various effective treatment modalities and novel treatment approaches have been developed for patients with MF/SS, which are based on an increased understanding of the pathobiol-ogy of the disease. However, experience with patients with other rare CTCL is limited, and the selection of treatment strategies remains more difficult.
Was this article helpful?